PUBLISHER: 360iResearch | PRODUCT CODE: 1618754
PUBLISHER: 360iResearch | PRODUCT CODE: 1618754
Non-Hodgkin Lymphoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy), Application (Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma), End-User - Global Forecast 2025-2030
The Non-Hodgkin Lymphoma Treatment Market was valued at USD 8.20 billion in 2023, expected to reach USD 8.84 billion in 2024, and is projected to grow at a CAGR of 7.91%, to USD 13.98 billion by 2030.
The scope of the Non-Hodgkin Lymphoma (NHL) treatment market encompasses the diagnosis, treatment, and management of various subtypes of NHL, focusing on pharmacologic interventions such as chemotherapy, immunotherapy, targeted therapy, and radiation therapy. It pertains to healthcare providers, pharmaceutical companies, researchers, and patients seeking effective, innovative treatments. The necessity for NHL treatment is underscored by its prevalence and the unmet need for long-term, effective treatment options. This market has diverse applications including hospitals, cancer research institutes, and specialty clinics, with growing demand fueled by advances in precision medicine and increased healthcare expenditure. The end-use scope covers patients across demographics and stages of NHL, from initial diagnosis to relapse or remission monitoring. Market insights reveal growth influenced by the increasing incidence of NHL, advances in biotechnology, and the approval of novel treatment options. Challenges such as high treatment costs, adverse treatment-related side effects, and the complexity of NHL subtypes create hurdles for consistent patient outcomes. Opportunities arise with the advent of CAR T-cell therapy and bispecific antibodies, presenting significant potential for improved efficacy and personalized care. Recommendations include investing in R&D for innovative therapies, leveraging partnerships for enhanced clinical trials, and focusing on developing cost-effective treatment regimens. Constraints include stringent regulatory environments and reimbursement issues that may affect market accessibility. The best areas for innovation and research lie in enhancing the efficacy of immunotherapies, integrating artificial intelligence for prognosis and treatment strategies, and exploring combination therapies that combine different treatment modalities to improve patient outcomes. The NHL treatment market is competitive and dynamic, with a robust focus on scientific advancements, offering substantial potential for businesses dedicated to improving the quality of life and survival rates for NHL patients.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 8.20 billion |
| Estimated Year [2024] | USD 8.84 billion |
| Forecast Year [2030] | USD 13.98 billion |
| CAGR (%) | 7.91% |
Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Non-Hodgkin Lymphoma Treatment Market
The Non-Hodgkin Lymphoma Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.
- Market Drivers
- Rising prevalence of non-Hodgkin lymphoma disease
- The launch of promising drugs and drug approval for lymphomas
- Emphasis on NHL patient prognosis and standard of care in front-line treatment regimens
- Market Restraints
- High cost of the treatment and certain side effects
- Market Opportunities
- Increase in research and development of therapeutic drugs against the disease
- Rising investments from government and non-profit organizations
- Market Challenges
- Stringent regulations for cancer treatment options
Porter's Five Forces: A Strategic Tool for Navigating the Non-Hodgkin Lymphoma Treatment Market
Porter's five forces framework is a critical tool for understanding the competitive landscape of the Non-Hodgkin Lymphoma Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.
PESTLE Analysis: Navigating External Influences in the Non-Hodgkin Lymphoma Treatment Market
External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Non-Hodgkin Lymphoma Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.
Market Share Analysis: Understanding the Competitive Landscape in the Non-Hodgkin Lymphoma Treatment Market
A detailed market share analysis in the Non-Hodgkin Lymphoma Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.
FPNV Positioning Matrix: Evaluating Vendors' Performance in the Non-Hodgkin Lymphoma Treatment Market
The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Non-Hodgkin Lymphoma Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.
Strategy Analysis & Recommendation: Charting a Path to Success in the Non-Hodgkin Lymphoma Treatment Market
A strategic analysis of the Non-Hodgkin Lymphoma Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.
Key Company Profiles
The report delves into recent significant developments in the Non-Hodgkin Lymphoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Aurobindo Pharma, Bayer AG, Cipla Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Hetero Drugs Ltd., Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Janssen Global Services, LLC, Kyowa Kirin Co., Ltd., Lupin Ltd., Merck KGaA, Nordic Nanovector ASA by Thor Medical, Novartis AG, Pharmacyclics, LLC, Salvavidas Pharmaceutical Pvt. Ltd., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Pharmaceuticals.
Market Segmentation & Coverage
This research report categorizes the Non-Hodgkin Lymphoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Based on Treatment Type, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy, Stem Cell Transplantation, and Targeted Therapy.
- Based on Application, market is studied across Diffuse Large B-cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma.
- Based on End-User, market is studied across Cancer Centers, Home Care, and Hospitals.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
The report offers a comprehensive analysis of the market, covering key focus areas:
1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.
2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.
3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.
4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.
5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.
The report also answers critical questions to aid stakeholders in making informed decisions:
1. What is the current market size, and what is the forecasted growth?
2. Which products, segments, and regions offer the best investment opportunities?
3. What are the key technology trends and regulatory influences shaping the market?
4. How do leading vendors rank in terms of market share and competitive positioning?
5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising prevalence of non-Hodgkin lymphoma disease
- 5.1.1.2. The launch of promising drugs and drug approval for lymphomas
- 5.1.1.3. Emphasis on NHL patient prognosis and standard of care in front-line treatment regimens
- 5.1.2. Restraints
- 5.1.2.1. High cost of the treatment and certain side effects
- 5.1.3. Opportunities
- 5.1.3.1. Increase in research and development of therapeutic drugs against the disease
- 5.1.3.2. Rising investments from government and non-profit organizations
- 5.1.4. Challenges
- 5.1.4.1. Stringent regulations for cancer treatment options
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.2.1. Treatment type: Chemotherapy treatments to prevent the spread of cancer to other parts of the body
- 5.2.2. Application: Utilization of immunotherapy and radiation in advanced stages treatment of diffuse large B cell lymphoma (DLBCL)
- 5.2.3. End-user: Increasing adoption of novel strategies for NHL treatment in hospitals
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
- 5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
6. Non-Hodgkin Lymphoma Treatment Market, by Treatment Type
- 6.1. Introduction
- 6.2. Chemotherapy
- 6.3. Immunotherapy
- 6.4. Radiation Therapy
- 6.5. Stem Cell Transplantation
- 6.6. Targeted Therapy
7. Non-Hodgkin Lymphoma Treatment Market, by Application
- 7.1. Introduction
- 7.2. Diffuse Large B-cell Lymphoma
- 7.3. Follicular Lymphoma
- 7.4. Mantle Cell Lymphoma
8. Non-Hodgkin Lymphoma Treatment Market, by End-User
- 8.1. Introduction
- 8.2. Cancer Centers
- 8.3. Home Care
- 8.4. Hospitals
9. Americas Non-Hodgkin Lymphoma Treatment Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
10. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
11. Europe, Middle East & Africa Non-Hodgkin Lymphoma Treatment Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
12. Competitive Landscape
- 12.1. Market Share Analysis, 2023
- 12.2. FPNV Positioning Matrix, 2023
- 12.3. Competitive Scenario Analysis
- 12.3.1. EPKINLY (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- 12.3.2. Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies
- 12.3.3. Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
- 12.4. Strategy Analysis & Recommendation
Companies Mentioned
- 1. AstraZeneca PLC
- 2. Aurobindo Pharma
- 3. Bayer AG
- 4. Cipla Inc.
- 5. Dr. Reddy's Laboratories Ltd.
- 6. Eli Lilly and Company
- 7. F. Hoffmann-La Roche Ltd.
- 8. Gilead Sciences, Inc.
- 9. GlaxoSmithKline PLC
- 10. Hetero Drugs Ltd.
- 11. Hikma Pharmaceuticals PLC
- 12. Intas Pharmaceuticals Ltd.
- 13. Janssen Global Services, LLC
- 14. Kyowa Kirin Co., Ltd.
- 15. Lupin Ltd.
- 16. Merck KGaA
- 17. Nordic Nanovector ASA by Thor Medical
- 18. Novartis AG
- 19. Pharmacyclics, LLC
- 20. Salvavidas Pharmaceutical Pvt. Ltd.
- 21. Sanofi S.A.
- 22. Takeda Pharmaceutical Company Limited
- 23. Teva Pharmaceutical Industries Ltd.
- 24. Zydus Pharmaceuticals
LIST OF FIGURES
- FIGURE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH PROCESS
- FIGURE 2. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2023 VS 2030
- FIGURE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
- FIGURE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
- FIGURE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 12. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 13. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 14. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 15. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 16. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 17. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 20. NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
- FIGURE 21. NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
- TABLE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 6. NON-HODGKIN LYMPHOMA TREATMENT MARKET DYNAMICS
- TABLE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 13. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 14. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
- TABLE 15. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
- TABLE 16. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
- TABLE 17. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 18. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 19. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 20. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 21. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 22. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 23. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 24. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 25. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 26. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 27. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 28. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 29. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 30. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 31. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 32. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 33. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 34. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 35. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 36. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 37. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 38. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 39. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 40. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 41. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 42. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 43. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 44. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 45. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 46. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 47. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 48. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 49. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 50. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 51. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 52. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 53. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 54. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 55. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 56. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 57. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 58. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 59. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 60. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 61. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 62. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 63. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 64. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 65. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 66. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 67. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 68. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 69. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 70. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 71. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 72. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 73. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 74. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 75. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 76. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 77. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 78. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 79. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 80. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 81. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 82. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 83. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 84. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 85. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 86. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 87. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 88. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 89. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 90. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 91. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 92. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 93. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 94. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 95. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 96. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 97. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 98. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 99. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 100. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 101. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 102. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 103. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 104. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 105. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 106. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 107. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 108. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 109. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 110. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 111. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 112. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 113. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 114. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 115. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 116. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 117. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 118. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 119. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 120. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 121. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 122. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 123. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 124. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 125. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 126. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 127. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 128. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 129. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 130. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 131. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 132. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 133. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 134. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 135. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 136. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 137. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 138. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 139. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 140. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 141. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 142. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 143. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 144. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 145. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 146. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
- TABLE 147. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 148. NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 149. NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
